I sent board members this email:
************************************
Hello,
There is a webcast today about Onvansertib Clinical Development Program, but there seems not to be any means to participate in this discussion. That's why I send this email to make my comments.
You must have noticed, Novartis bought Endocyte just a couple weeks ago. In reality Novartis bought one drug candidate for prostate cancer treatment. This candidate has entered phase 3 development just about half a year ago.
There are several reasons to claim, Onvansertib is more valuable candidate than the one Novartis did pay that $2.1 billion for:
1. prostate cancer only concerns a bit less than half of population. Bone marrow and blood seems to be in every individual. Onvansertib has twice the market area compared to prostate cancer drug.
2. Most prostate cancer patients can live several years even if they were not treated at all. Prostate cancer does not have very aggressive nature and there are already some competitive treatments for it. However AML can be treated only for quite small portion. 80% of AML patients have something like half a year lifetime left without any effective opportunity to treat them. AML is way more aggressive cancer compared to prostate cancer.
3. Onvansertib had exceptionally fine results in combination therapy in phase 2 investigations. It seems to have better results than that prostate cancer in same phase.
4. Onvansertib might benefit patients with other cancer types too, while this prostate cancer drug candidate is very highly specific to only this particular prostate cancer having prostate specific receptors. Onvansertib might have much wider market area, but that prostate cancer will probably only benefit those prostate cancer patients.
On top of this there seems not to be any obvious reasons why that prostate cancer drug should be considered better than Onvansertib. Scale is heavily in favor of Onvansertib.
For these reasons I hope you do not sell Onvansertib for too low price. I am an owner of Trovagene stocks myself and I know very well how good results tend to benefit other parties than present owners. If there seems to be coming significant income, companies tend to arrange share offerings to arrange majority of this kind of company to some new owners. Even Endocyte did this. Those who owned that company a year ago got only some 10% of sales price because they did dilute shares twice this year.
I prefer you finding a buyer for Onvansertib now without arranging dilutive offerings first. Onvansertib is so potential candidate, there must be several drug companies interested in buying it and paying at least as much as Novartis did pay for that prostate cancer candidate.
Have a nice day.
WBR: xxxxxx
AI
